login
  Password reminder
Vascular News
Contact the editor Visit Vascular News Twitter feed Visit Vascular News Facebook page
 

Angel Catheter is CE-marked


Monday, 21 May 2012 10:07
Angel Catheter
Angel Catheter

BiO2 Medical has announced that it has received CE mark approval for the Angel Catheter, a nitinol inferior vena cava (IVC) filter, permanently attached to a central venous catheter (CVC) for the use of preventing pulmonary embolism in critically ill patients with venous thromboembolism for whom anticoagulation therapy is temporarily contraindicated. 


According to a company release, the Angel device is the first IVC filter with a prophylactic use indication, and allows attending physicians the ability to place an IVC filter bedside in the intensive care unit, in a procedure resembling a routine CVC placement procedure.

“Obtaining the CE clearance for commercialisation of the Angel catheter in Europe is a significant step in our goal to provide an alternative for critically ill patients at high risk of pulmonary embolism. It also validates a long and complex process of extensive testing for the use of our device as a prophylaxis against pulmonary embolism,” said Luis F Angel, chief medical officer, BiO2 Medical, and inventor of the Angel catheter.




Add New Comment

Most popular


ROADSTER trial studying new path to carotid revascularisation completes patient enrolment
Friday, 18 Jul 2014
The trial was the first of its kind to study the treatment of carotid artery stenosis by placing a stent via direct access to the common carotid artery in the neck in an entirely new minimally ... ROADSTER trial studying new path to carotid revascularisation completes patient enrolment

Endovascular-first strategy for aortoiliac lesions irrespectively of TASC category
Thursday, 17 Jul 2014
Two-year data from a prospective, multicentre study suggest that endovascular therapy with stenting may be considered the preferred first-line treatment option for aortoiliac lesions, irrespectively ... Endovascular-first strategy for aortoiliac lesions irrespectively of TASC category

Similar results with elective post-EVAR open conversion and primary open juxtarenal aneurysm repair for type Ia endoleak
Wednesday, 13 Aug 2014
Elective open surgical conversion for type Ia endoleak after endovascular aneurysm repair (EVAR) is not associated with increased morbidity or mortality compared with open juxtarenal aneurysm repair ... Similar results with elective post-EVAR open conversion and primary open juxtarenal aneurysm repair for type Ia endoleak

Features


SPECT can predict cardiovascular mortality in elective aneurysm repair patients
Wednesday, 12 Mar 2014
Kimihiro Komori and Yosuke Inoue analyse the results of a study that concluded that preoperative pharmacologic stress myocardial perfusion SPECT is not only safe, but is also a useful method to ... SPECT can predict cardiovascular mortality in elective aneurysm repair patients

Hybrid techniques for the arch: are they effective and durable?
Monday, 17 Feb 2014
Piergiorgio Cao writes that despite the perioperative mortality risk, the late outcome of endovascular arch repair presents a low rate of aorta-related deaths and reinterventions and acceptable mid-... Hybrid techniques for the arch: are they effective and durable?

Profiles


Cliff Shearman
Thursday, 03 Jul 2014
A former president of the Vascular Society of Great Britain and Ireland, Cliff Shearman was ... Cliff Shearman

Andrew Holden
Tuesday, 11 Feb 2014
Andrew Holden has been involved in the investigation of several endovascular devices for the ... Andrew Holden

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions